Next Treatments
Back to Eczema

611

TypeInjection StagePhase 3 Latest updateUpdated recently. Aug 18, 2026Phase 3 study completed

What stands out

  • Same target as Dupixent
  • Binds to IL-4 receptor, the docking point for both the IL-4 and IL-13 signals
  • Injection every week, 2, 3 or 4 weeks in trials
Derived from NCT07767253 · NCT07042126 · NCT06173284 · NCT05641558 · UniProt P24394 · US label: Dupixent · This is a summary of public records for informational purposes only. It is not medical advice.

History

Earliest recorded event: Oct 18, 2021. This timeline shows events collected by Eczema Radar and may not include the treatment’s full history. Study details reflect the latest registry record available here.

  • Aug 18, 2026Phase 3 trial completedEvaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis ClinicalTrials.gov NCT06554847
  • Aug 17, 2026Phase 3 trial postedEvaluation of 611 in Chinese Children With Moderate to Severe Atopic Dermatitis(AD) ClinicalTrials.gov NCT07767253
  • May 25, 2026Phase 1/2 trial completedEvaluation of 611 in Chinese Children and Adolescents With Moderate to Severe Atopic Dermatitis ClinicalTrials.gov NCT06324812
  • Nov 20, 2025Phase 3 trial completedEvaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis ClinicalTrials.gov NCT06173284
  • Oct 20, 2025Phase 3 main data collectedEvaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis ClinicalTrials.gov NCT06554847
  • Sep 26, 2025Phase 3 main data collectedEvaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis ClinicalTrials.gov NCT06173284
  • Aug 5, 2025Phase 3 trial startedEvaluation of 611 in Chinese Adolescents With Moderate to Severe Atopic Dermatitis ClinicalTrials.gov NCT07042126
  • Jun 27, 2025Phase 1 trial postedA Study of Two Different Formulations of 611 in Healthy Adult Subjects in China ClinicalTrials.gov NCT07042113
  • Sep 23, 2024Phase 3 trial startedEvaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis ClinicalTrials.gov NCT06554847
  • Jul 10, 2024Phase 1/2 trial startedEvaluation of 611 in Chinese Children and Adolescents With Moderate to Severe Atopic Dermatitis ClinicalTrials.gov NCT06324812
  • Jan 22, 2024Phase 3 trial startedEvaluation of 611(Recombinant Humanized Anti-interleukin-4 Receptor Alpha IgG4 Monoclonal Antibody) in Chinese Adults With Moderate to Severe Atopic Dermatitis ClinicalTrials.gov NCT06173284
  • Sep 20, 2023Phase 2 trial completedEvaluation of 611 in Chinese Adults With Moderate to Severe Atopic Dermatitis ClinicalTrials.gov NCT05544591
  • Jul 10, 2023Phase 2 main data collectedEvaluation of 611 in Chinese Adults With Moderate to Severe Atopic Dermatitis ClinicalTrials.gov NCT05544591
  • Oct 26, 2022Phase 2 trial startedEvaluation of 611 in Chinese Adults With Moderate to Severe Atopic Dermatitis ClinicalTrials.gov NCT05544591
  • Oct 21, 2022Phase 1/2 trial completedEvaluation of 611 in Chinese Adult Patients With Moderate-to-Severe Atopic Dermatitis ClinicalTrials.gov NCT05641558
  • Oct 18, 2021Phase 1/2 trial startedEvaluation of 611 in Chinese Adult Patients With Moderate-to-Severe Atopic Dermatitis ClinicalTrials.gov NCT05641558

Sources

Trials